Alkermes plc(ALKS)Earnings, Financials & Key RatiosAlkermes plc (ALKS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to maintain consistent profitability, highlighted by the recent $66.5M net loss in 2026Q1, warrants a wait-and-see approach until royalty arbitration risks are resolved.
Alkermes plc (ALKS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Alkermes plc (ALKS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.40vs $0.57+29.8% | $393Mvs $363M+8.2% |
| Q1 2026 | Feb 25, 2026 | $0.34vs $0.43-20.9% | $385Mvs $379M+1.5% |
| Q4 2025 | Oct 28, 2025 | $0.49vs $0.42+16.7% | $394Mvs $380M+3.8% |
| Q3 2025 | Jul 29, 2025 | $0.52vs $0.41+26.8% | $391Mvs $355M+10.2% |
Recent stock market news and headlines for Alkermes plc (ALKS)
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
On June 23, 2026, Alkermes PLC (ALKS) shares rose 4.3% today, bringing the current price to $48.06. Over the past week, shares increased by 9.0%, and have seen
Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis.
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the study's dual primary endpoints, demonstrating statistically significant and clinically meaningful improvements from baseline compared to placebo on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week eight in adults with NT2 (n=.
Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.
Key metrics vs top competitors for Alkermes plc (ALKS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $55.22 | $9.2B | 38.62 | -5.25% | 16.37% | 14.72% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $249.76 | $12.85B | -67.87 | 65.55% | -26.59% | -260.01% | — | |
| $5.59 | $2.47B | 9.90 | 50.54% | 8.99% | 14.24% | — |
Alkermes plc (ALKS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Alkermes plc (ALKS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Feb 25, 2026·SEC
Feb 25, 2026·SEC
Get notified when ALKS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alkermes plc (ALKS) stock FAQ — growth, dividends, profitability & financials explained
Alkermes plc (ALKS) reported $1.56B in revenue for fiscal year 2025. This represents a 7780% increase from $19.8M in 1996.
Alkermes plc (ALKS) saw revenue decline by 5.2% over the past year.
Yes, Alkermes plc (ALKS) is profitable, generating $152.7M in net income for fiscal year 2025 (16.4% net margin).
Alkermes plc (ALKS) has a return on equity (ROE) of 14.7%. This is reasonable for most industries.
Alkermes plc (ALKS) generated $391.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
